Cytospire Therapeutics News

Cytospire Secures $83M for Cancer Engagers

May 5, 2026

London biotech Cytospire raised £61M ($83M) to advance pan-gamma delta T-cell engagers, led by CYT X300 for EGFR-positive solid tumours.